RTRX - Retrophin, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Retrophin, Inc.

3721 Valley Centre Drive
Suite 200
San Diego, CA 92130
United States
760-260-8600
http://www.retrophin.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees214

Key Executives

NameTitlePayExercisedYear Born
Ms. Laura M. Clague CPACFO & Sr. VP592.98kN/A1959
Dr. William E. RoteSr. VP and Head of R&D622.76kN/A1963
Dr. Noah L. RosenbergChief Medical Officer831.49kN/A1967
Dr. Eric M. Dube Ph.D.Pres, CEO & DirectorN/AN/A1973
Chris Cline CFAVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; CNSA-001, an orally bioavailable proprietary form of sepiapterin that is in phase II clinical trial for the treatment of phenylketonuria; and liquid ursodeoxycholic acid, a liquid formulation of ursodeoxycholic acid for the treatment of primary biliary cholangitis. The company has a cooperative research and development agreement with National Center for the identification and development of therapeutics for Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.

Corporate Governance

Retrophin, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 5. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 2; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.